在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J101研究则显示治疗HER2+、HR+/HER2-、TNBC的ORR分别为43%、30%和23%[12]。 ...
New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast CancerDiagnostic criteriaPathologyWHO classificationBreast CancerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, ...
PALOMA-2是一项III期研究,结果显示在标准内分泌治疗基础上加CDK抑制剂可显著改善ER+/HER2-晚期乳腺癌一线治疗的疗效,该研究证实了Palbociclib和来曲唑联合疗法作为一线治疗ER+晚期乳腺癌绝经后妇女的疗效和安全性。研究还显示Palbociclib联合来曲唑的临床获益率...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J101研究则显示治疗HER2+、HR+/HER2-、TNBC的ORR分别为43%、30%和23%[12]。 ...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J101研究则显示治疗HER2+、HR+/HER2-、TNBC的ORR分别为43%、30%和23%[12]。
[10]Robertson J, Gogitidze T, Katashvili Z, et al. SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2...
[10]Robertson J, Gogitidze T, Katashvili Z, et al. SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer. 2023 SABCS. Abstract RF01-01. ...
HER2+/ER+乳腺癌属于Luminal型乳腺癌中特殊的一个亚型,单纯的内分泌治疗疗效欠佳,通常推荐采用内分泌治疗联合抗HER2治疗。近年来,分子生物学的研究提示,HER2和ER通路之间存在交互作用,可以通过进一步活化RB1促进肿瘤细胞生长。如果采用同时靶向HER2、ER和RB1的联合靶向治疗,是否可以进一步提高患者的疗效呢?近期发布在《La...
[3]Oliveira M, Pominchuck D, Nowecki Z, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. 2022 SABCS. Abstract GS3-02. ...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.